Bright Minds Biosciences (Bright Minds Biosciences) Long-Term Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Long-Term Capital Lease Obligation?

Bright Minds Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Bright Minds Biosciences's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.01 Mil) to Sep. 2023 ($0.00 Mil) but then stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Bright Minds Biosciences's annual Long-Term Capital Lease Obligation increased from Sep. 2021 ($0.00 Mil) to Sep. 2022 ($0.05 Mil) but then declined from Sep. 2022 ($0.05 Mil) to Sep. 2023 ($0.00 Mil).

Bright Minds Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Bright Minds Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Long-Term Capital Lease Obligation Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Long-Term Capital Lease Obligation

0.05

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial												0.04	0.03	0.01	-	-

Bright Minds Biosciences (NAS:DRUG) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Bright Minds Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.